Stifel lowered the firm’s price target on Bruker (BRKR) to $57 from $70 and keeps a Hold rating on the shares. Bruker continues to show ...

Barclays lowered the firm’s price target on Bruker (BRKR) to $60 from $65 and keeps an Overweight rating on the shares. The firm sees elevated ...

Bruker Corporation today announced the launch of the VERTEX NEO Platform today with its first product, the VERTEX NEO R. This ...

Bruker Corporation announced the launch of the LUMOS™ II ILIM , a quantum cascade laser (QCL) based infrared imaging microscope. The new LUMOS II ILIM redefines performance standards ...

Bruker expects full-year earnings in the range of $2.67 to $2.72 per share, with revenue in the range of $3.47 billion to $3.54 billion. Bruker shares have fallen 12% since the beginning of the year.

The VERTEX 80 and the VERTEX 80v vacuum FT-IR spectrometers from Bruker are based on the actively aligned UltraScan ™ interferometer, which provides PEAK spectral resolution. The precise linear ...

BILLERICA, Mass., February 07, 2025--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before market opening ...

Discover key takeaways from Bruker Corporation's Q4 2024 earnings call, highlighting strong diagnostics, semiconductor growth, and confident 2025 ...

Bruker Corporation (NASDAQ: BRKR) is undervalued, trading below its fair value of $74, offering significant upside potential due to its strategic acquisitions and improving book value per share.

Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before market opening on Thursday, February 13, 2025. The Company will host a ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, according to a Thursday filing in Delaware ...